SAMSUNG-ELECTRONICS
2.9.2021 10:02:06 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced the ISOCELL HP1, the industry’s first 200-megapixel (MP) image sensor with 0.64μm pixels, and ISOCELL GN5, the first image sensor to adopt all-directional focusing Dual Pixel Pro technology with two photodiodes in a single 1.0μm pixel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005321/en/
“Samsung has been pioneering ultrafine pixel technologies that are taking high-resolution image sensors to the next level,” said Duckhyun Chang, executive vice president of sensor business at Samsung Electronics. “With the ISOCELL HP1 that is breaking barriers and ISOCELL GN5 bringing ultrafast auto focus, Samsung will continue to lead the trend for next-generation mobile imaging technologies.”
ISOCELL HP1: Capture the world in breathtaking 200MP and crystal sharp 8K video
The ISOCELL HP1 is the industry’s first mobile image sensor to support 200MP. Based on Samsung’s most advanced 0.64μm-sized pixels, the ISOCELL HP1 brings such ultrahigh resolution in a small package that fits comfortably in today’s handheld devices. With the ISOCELL HP1, pictures hold an astonishing amount of detail that helps the image stay sharp even when cropped or resized.
For ultimate low-light photography, the ISOCELL HP1 features an all-new ChameleonCell technology, a pixel-binning technology that uses a two-by-two, four-by-four or full pixel layout depending on the environment. In a low-lit environment, the HP1 transforms into a 12.5MP image sensor with large 2.56μm pixels by merging 16 neighboring pixels. The newly formed 2.56μm pixel is capable of more light absorption and sensitivity, producing brighter and clearer photos in in-doors or in the evening. In bright outdoor environments, the sensor’s 200-million pixels can capture ultra-high-definition photography on mobile devices.
The ISOCELL HP1 can take 8K videos at 30 frames-per-second (fps) with minimum loss in the field of view. The HP1 merges four neighboring pixels to bring the resolution down to 50MP or 8,192 x 6,144 to take 8K (7,680 x 4,320) videos without the need to crop or scale down the full image resolution.
ISOCELL GN5: Lock on instantly and take super-sharp hi-res images with all-directional autofocus
The ISOCELL GN5 is the industry’s first 1.0μm image sensor to integrate Dual Pixel Pro, an all-directional autofocusing technology, that can substantially boost autofocusing capabilities. This technology places two photodiodes, the smallest in the industry, within each 1.0μm pixel of the sensor either horizontally or vertically to recognize pattern changes in all directions. With one million phase-detecting multi-directional photodiodes covering all areas of the sensor, the ISOCELL GN5’s autofocusing becomes instantaneous, enabling sharper images in either bright or low-lit environments.
The image sensor also makes use of Samsung’s proprietary pixel technology, which applies Front Deep Trench Isolation (FDTI) on a Dual Pixel product for the first time in the industry. Despite the microscopic photodiode size, FDTI enables each photodiode to absorb and hold more light information, improving the photodiodes’ full-well capacity (FWC) and decreasing crosstalk within the pixel.
Samples of Samsung ISOCELL HP1 and GN5 are currently available.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and ISOCELL 2.0 technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005321/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 13:20:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release
Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom